ango_8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 3, 2008
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
000-50761
|
11-3146460
|
(State
or Other Jurisdiction
of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
603
Queensbury Avenue, Queensbury, New
York 12804
|
(Address
of Principal Executive
Offices) (Zip
Code)
|
|
(518)
798-1215
|
(Registrant’s
telephone number, including area
code)
|
Check
the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
|
Item
2.02 Results of Operations and Financial Condition
On
January 3, 2008, AngioDynamics, Inc. (the “Company”) issued a press release, a
copy of which is attached as Exhibit 99.1, announcing its financial results
for
the second quarter of fiscal 2008, which ended on November 30, 2007, and that
it
will hold a conference call beginning at 4:30 p.m. Eastern time, which will
also
be webcast live, to discuss the announcement.
The
information provided pursuant to this Item 2.02 of this current report,
including the information contained in Exhibit 99.1 is being furnished pursuant
to such Item and shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the
liabilities of that Section.
Forward-Looking
Statements
This
document and its attachments include "forward-looking statements" intended
to
qualify for the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Investors can identify these statements by the
fact that they do not relate strictly to historical or current facts. These
statements contain words such as "expect,"
"reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will,"
"predict," "project," "might," "intend," "potential," "could," "would,"
"should," "estimate," "seek," "continue," "pursue," or "our future success
depends," or the negative or other variations thereof or comparable terminology,
are intended
to identify such forward-looking statements. In particular, they include
statements relating to, among other things, future actions, strategies, future
performance, future financial results of the Company. These
forward-looking statements are based on current expectations and projections
about future events.
Investors
are cautioned that forward-looking statements are not guarantees of future
performance or results and involve risks and uncertainties that cannot be
predicted or quantified and, consequently, the actual performance or results
of
the Company may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, but
are not limited to, the factors described from time to time in the Company's
reports filed with the SEC, including the Company's Form 10-K for the fiscal
year ended June 2, 2007 and Form 10-Q for the period ended August 31, 2007,
financial community and rating agency perceptions of the Company; the effects
of
economic, credit and capital market conditions on the economy in general, and
on
medical device companies in particular; domestic and foreign health care reforms
and governmental laws and regulations; third-party relations and approvals,
technological advances and patents attained by competitors; and challenges
inherent in new product development, including obtaining regulatory
approvals. In addition
to the
matters described above, the ability of the Company to develop its products,
future actions by the FDA or other regulatory agencies, results of pending
or
future clinical trials, the outcome of pending patent litigation, overall
economic conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, and the effects on pricing from group
purchasing organizations and competition, may affect the actual results achieved
by the Company.
Any
forward-looking statements are made pursuant to the Private Securities
Litigation Reform Act of 1995 and, as such, speak only as of the date made.
The
Company disclaims any obligation to update the forward-looking
statements. Investors are cautioned not to place undue reliance on
these forward-looking statements which speak only as of the date stated, or
if
no date is stated, as of the date of this document.
Item
9.01 – Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release dated January 3, 2008.
|
SIGNATURE
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ANGIODYNAMICS,
INC.
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
January 4, 2008
|
|
|
By:
|
|
/s/
Joseph Gersuk
|
|
|
|
|
|
|
Joseph
Gersuk
|
|
|
|
|
|
|
Chief
Financial Officer
|
|
|
|
|
|
|
|
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release dated January 3, 2008.
|